<DOC>
	<DOC>NCT00212693</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease</brief_summary>
	<brief_title>Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1. Diagnosis of Parkinson's disease 2. Stage 2 Stage 4 of revised Hoehn &amp; Yahr severity score 3. Taking Ldopa/DCI without changing dose and regimen 4. Having motor complication 5. Other inclusion criteria as specified in the study protocol 1. Previous participation in ONO2506PO or ONO2506 protocol 2. Previous brain surgery for Parkinson's disease 3. Presence or history of serious cardiac disease 4. Other exclusion criteria as specified in the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>ONO-2506PO, Parkinson's disease</keyword>
</DOC>